

AperTO - Archivio Istituzionale Open Access dell'Università di Torino

Targeted and untargeted detection of fentanyl analogues and their metabolites in hair by means of UHPLC-QTOF-HRMS

This is a pre print version of the following article:

Original Citation:

Availability:

This version is available <http://hdl.handle.net/2318/1768930> since 2022-05-25T11:51:32Z

Published version:

DOI:10.1007/s00216-020-02994-x

Terms of use:

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)



Targeted and Untargeted detection of fentanyl analogs and their metabolites in hair by means of UHPLC-QTOF-HRMS

| | |
|-------------------------------|--|
| Journal: | <i>Analytical and Bioanalytical Chemistry</i> |
| Manuscript ID | Draft |
| Type of Paper: | Research Paper |
| Date Submitted by the Author: | n/a |
| Complete List of Authors: | Salomone, Alberto; Università degli Studi di Torino, Di Corcia, Daniele; Centro Regionale Antidoping, Negri, Pierre; SCIEX Kolia, Maria; University of Ioannina Amante, Eleonora; Università degli Studi di Torino Gerace, Enrico; Centro Regionale Antidoping, Vincenti, Marco; University of Torino, Chimica Analitica; Centro Regionale Antidoping e di Tossicologia , |
| Keywords: | hair, HRMS, QTOF, synthetic opioids, fentalogs, fentanyl |
| | |

SCHOLARONE™
Manuscripts



Settori di attività
tossicologia analitica – forense – industriale – veterinaria – dello sport
sicurezza alimentare, prevenzione antidoping

Torino, July 27th, 2020

Dear Editor,

I am pleased to submit the manuscript entitled "Targeted and Untargeted detection of fentanyl analogs and their metabolites in hair by means of UHPLC-QTOF-HRMS".

The work is new and original and is not under consideration elsewhere. In this manuscript, we describe a comprehensive and validated workflow that combines the use of UHPLC-QTOF-HRMS instrumentation with a simple hair samples extraction procedure for the detection of a variety of fentanyl analogues and metabolites. Besides the targeted analysis, we investigated 100 real samples by means of retrospective data analysis. This innovative approach based on untargeted analysis is very powerful, as it allows the identification of molecules which were not originally included in the panel of targeted analytes. In the modern drug scenario, the continuous introduction of new compounds makes the updating of targeted methods very challenging for all forensic laboratories. On the other hand, new approaches based on HRMS can offer new perspectives of investigation and drug surveillance. Similar innovative workflows will be beneficial to all subjects involved in drug analysis, and especially those working with fentanyl and new synthetic opioids.

Best regards.
Alberto Salomone

Targeted and Untargeted detection of fentanyl analogs and their metabolites in hair by means of UHPLC-QTOF-HRMS

A. Salomone^{1,2*}, D. Di Corcia¹, P. Negri³, M. Kolia⁴, E. Amante², E. Gerace¹, M. Vincenti^{1,2}

¹ *Centro Regionale Antidoping e di Tossicologia, Orbassano (TO), Italy*

² *Department of Chemistry, University of Turin, Torino, Italy*

³ *SCIEX, US*

⁴ *Department of Chemistry, University of Ioannina, Ioannina, Greece*

**Corresponding author*

E-mail address: alberto.salomone@unito.it

<https://orcid.org/0000-0002-8501-4799>

Abstract

Detection of new psychoactive substances and synthetic opioids is generally performed by means of targeted methods in mass spectrometry, as they generally provide adequate sensitivity and specificity. Unfortunately, new and unexpected compounds are continuously introduced in the illegal market of abused drugs, preventing timely updating of the analytical procedures. Moreover, the investigation of biological matrices is influenced by metabolism and excretion, in turn affecting the chance of past intake detectability. In this scenario, new opportunities are offered by both the non-targeted approaches allowed by modern UHPLC-HRMS instrumentation and the investigation of hair as the matrix of choice to detect long-term exposure to toxicologically relevant substances. In this study, we present a comprehensive and validated workflow that combines the use of UHPLC-QTOF-HRMS instrumentation with a simple hair samples extraction procedure for the detection of a variety of fentanyl analogues and metabolites. A simultaneous targeted and untargeted analysis was applied to 100 real samples taken from opiates users. MS and MS/MS data were collected for each sample. Data acquisition included a preliminary TOF-MS high-resolution scan followed by SWATH™ acquisition demonstrating considerable capability to detect expected and unexpected substances even at low concentration levels. The predominant diffusion of fentanyl was confirmed by its detection in 68 hair samples. Other prevalent analogs were furanylfentanyl (28 positive samples) and acetyl fentanyl (14 positive samples). Carfentanil, methylfentanyl, and ocfentanil were not found in any of the analyzed samples. Furthermore, the retrospective data

1
2
3 analysis based on untargeted acquisition allowed the identification of two fentanyl analogs, namely
4 β -hydroxyfentanyl and methoxyacetylfentanyl, which were not originally included in the panel of
5 targeted analytes.
6
7

8
9 **Keywords:** hair; HRMS; QTOF; synthetic opioids; fentalogs; fentanyl
10
11
12
13

14 **Introduction**

15
16 In the last decade, the general situation and world distribution of drugs of abuse has evolved
17 dramatically with the emergence of a large variety of new psychoactive substances (NPS). In
18 particular, the pattern of abused synthetic opioids progressed from the over-prescription of legal
19 analgesic drugs such as hydrocodone, oxycodone, and fentanyl, to the clandestine synthesis of new
20 fentanyl derivatives specifically produced for the illegal market [1,2]. Fentanyl and its analogs are
21 considered particularly risky for their extreme pharmacological effects, as the large and ever-
22 increasing outburst of lethal overdose cases in the U.S. clearly evidences [3]. These fatal overdoses
23 may either stem from the use of fentanyl and analogs as cutting/adulterant agents or simply as
24 substitutes for heroin. The easy accessibility of these powerful substances poses a major safety
25 concerns for both drug abusers and law enforcement officials exposed to the seized materials. The
26 timely detection of individual exposure to fentanyl and its analogs, potentially lethal even at low
27 dosage, represents a challenging objective for both their typically minuscule concentration in body
28 fluids and their chemical variability associated to minor structural changes of the parent drug.
29 Detection of fentanyl analogues can be performed in many biological matrices, including urine,
30 blood, saliva and hair. Unlike blood and urine, hair analysis is increasingly used to detect long-term
31 exposure to toxicologically relevant substances, as it offers a wide diagnostic window basically
32 dependent on the hair length [4]. Hair analysis has been repeatedly used to ascertain past exposure
33 and prevalence of different novel synthetic opioids (NSO) in the consumer's population.[5–14] .
34 The analytical methods currently available are generally based on the targeted detection of a limited
35 and well-defined list of compounds to monitor, usually chosen on the base of the national or
36 international reports, or alerts from national warning systems. One of the challenges in the
37 development of validated methods for the analysis and identification of NSO within a rapidly
38 changing and dynamic market is that analytical reference materials may not be commercially
39 available or require long time to be synthesized. Therefore, most toxicological laboratories are
40 stimulated to create up-to-date targeted methods, capable of detecting dozens of compounds whose
41 list is constantly renovated. Nevertheless, effective approaches for NSO screening may benefit from
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 recent technological developments of analytical instrumentation and methods [15]. In particular,
4 untargeted screening methods are devoted to a comprehensive investigation of the tested samples,
5 by i) looking for compounds structurally similar to the targeted drugs, ii) proposing their identities,
6 and iii) confirming the new findings and add them to the target list. Preliminary HRMS-based
7 approaches have been recently proposed, in order to screen for different classes of drugs in hair [8],
8 for fentanyl analogues in blood [16], or for emerging synthetic cannabinoids [17]. In our study, we
9 aimed to develop, validate and apply a new analytical method based on a simultaneous targeted and
10 untargeted approach. The comprehensive workflow combined the use of a UHPLC-QTOF-HRMS
11 system, with a simple extraction procedure for specific and sensitive detection of fentanyl analogues
12 in hair. The untargeted investigation based on a retrospective data analysis proved qualified to
13 perform untargeted screening without the need of analytical standards.
14
15
16
17
18
19
20
21

22 **Experimental**

23 *Reagents and Standards*

24
25 Reagents and standards of furanylfentanyl, 4-fluorobutyrfentanyl, acrylfentanyl, butyrylfentanyl
26 and 4-anilino-N-phenethyl-piperidine (4-ANPP) were produced by Chiron (Trondheim, Norway).
27 Acetylfentanyl and carfentanil were obtained by Toronto Research Chemicals (North York,
28 Canada) while ocfentanil and norfentanyl were purchased from Sigma-Aldrich (Milan, Italy).
29 Cyclopropylfentanyl, α -methylylfentanyl and β -hydroxyfentanyl were provided by National Institute
30 of Health (ISS). Fentanyl, and the deuterated internal standards (norfentanyl- d_5 , fentanyl- d_5) were
31 produced by Cerilliant (Round Rock, Texas, US). All other chemicals were purchased from Sigma-
32 Aldrich (Milan, Italy). Ultra-pure water was obtained using a Milli-Q® UF-Plus apparatus
33 (Millipore, Bedford, MA, USA). All stock standard solutions were prepared in methanol at 1
34 mg/mL and stored at -20°C until used. Working solutions were prepared at the final concentration
35 of 1000 ng/mL by dilution with methanol.
36
37
38
39
40
41
42
43
44
45
46
47
48

49 *Sample preparation*

50
51 About 50 mg of head hair were twice-washed with dichloromethane and then methanol (1 mL of
52 solvent, vortex mixed for 3 minutes). The solvent washes were removed following each vortex
53 mixing steps. Following the washing steps, hair was dried at room temperature using a gentle
54 nitrogen flow and subsequently grinded with a ball mill (Precellys 24, Bertin Instruments,
55 Montigny-le-Bretonneux, France). The resulting hair sample was spiked with 2.5 μL of an internal
56 standard mixture yielding a final concentration of 50 pg/mg. 1 mL of HPLC grade methanol was
57
58
59
60

1
2
3 added and the mixture was incubated at 55°C for 15 hours without stirring. Following the
4 incubation step, 100 µL of the organic phase was transferred in a UHPLC vial and an aliquot of 3
5 µL was directly injected into the UHPLC-HRMS/MS system. Whenever the real samples
6 concentrations were found to exceed the highest calibration point, the final extracts were diluted
7 with methanol and re-injected into the system.
8
9
10
11
12

13 *Instrumentation*

14
15
16 UHPLC separation was performed on a Phenomenex Kinetex C18 column (100 × 2.1 mm, 1.7 µm,
17 00D-4475-AN) at 45 °C on the SCIEX ExionLC™ AC system. Mobile phases consisted of water
18 (A) and acetonitrile (B), both with 5 mM of formic acid. The LC flow rate was 0.5 mL and the
19 mobile phase eluted under the following linear gradient conditions: (A:B, v:v) isocratic elution at
20 95:5 for 0.5 min, from 95:5 to 50:50 in 4.5 min, isocratic elution at 50:50 for 0.5 min and final re-
21 equilibration for 2.5 min to the initial condition before each injection. Total run time was 7 min.
22
23
24
25

26 All analyses were performed using a quadrupole time-of-flight SCIEX X500R QTOF mass
27 spectrometer (Sciex, Darmstadt, Germany) equipped with a Turbo V™ ion source operating in
28 electrospray positive-ion mode. MS and MS/MS data were collected for each sample using
29 SWATH™ Acquisition mode. Data acquisition included a preliminary TOF-MS high-resolution
30 scan followed by SWATH™ Acquisition using variable window setup (12 windows covering mass
31 range from 230 to 450 m/z at 0.02 resolving power), resulting in a final cycle time of 0.555 sec.
32
33
34
35
36
37 Data were acquired using SCIEX OS 1.5 Software. The full list of the MS/MS transitions for the
38 analytes and internal standards are presented in Table 1.
39
40
41

42 *Data Analysis and processing*

43
44 Data processing was performed using SCIEX OS 1.5 Software for positive analyte identification
45 based on confidence criteria. The four main confidence criteria used include precursor and fragment
46 mass error +/- 5 ppm and library hit score (L). Subsequently, a combined score (C) was calculated
47 based on the third confidence categories (MRIL) with custom weightings.
48
49

50 A data processing method was developed to review the SWATH™ Acquisition data. While data
51 acquisition was set in the non-targeted mode, data processing was organized with targeted
52 approach, using a list of 12 targeted analytes and 2 internal standards to initially screen the dataset.
53
54 Then, further screening of related and potentially interesting compounds not initially targeted was
55 achieved by querying the software to look for their protonated exact mass. The full list of these
56 molecules is shown in Table S1 When an unknown peak was observed, additional software
57 processing and functional relationship search was activated to determine the potential candidate
58
59
60

1
2
3 formula and structure. The workflow utilizes the experimentally determined high-resolution and
4 accurate mass of the detected peak and the FormulaFinder feature to generate candidate empirical
5 formulae for the corresponding molecule. These candidate formulae were coupled with MS/MS
6 fragmentation spectra and matched with the extensive ChemSpider database to verify whether the
7 predicted in-silico fragmentation pattern of the candidate structures corresponded to experimental
8 MS/MS spectra. Once the exact mass and isotopic profile of the unknown molecule is selected, the
9 software links these features to the ChemSpider site which is a free chemical structure database
10 providing fast text and structure search access to over 67 million structures from hundreds of data
11 sources. ChemSpider can generate candidate structures for each formula with a matching of HR-
12 MS/MS spectra to predicted fragment ions [18].
13
14
15
16
17
18
19

20 21 22 *Real samples*

23
24 Real hair samples were collected in the United States between November 2016 and August 2018.
25 All samples selected for the present study had previously tested positive to common opiates. A total
26 of 100 samples was analyzed. All samples were analyzed in their entire length (range 1-20 cm,
27 mean value 4.0 cm).
28
29
30

31 32 *Validation*

33
34 The calibration process was conducted with an optimized procedure, requiring the preparation of
35 three replicates of the calibration curves for the targeted compounds in three different days for a
36 total of nine calibration curves [19,20]. Several validation parameters were determined from these
37 data, including linearity range and calibration model, selectivity, specificity, limit of detection
38 (LOD), limit of quantification (LOQ), trueness, intra and inter-assay precision, and repeatability.
39 The linearity was evaluated within the concentration range of 2.0–100 pg/mg. The best calibration
40 model was determined using the RStudio routine developed by Desharnais et al. [21,22], which
41 included the study of homo- vs. heteroscedasticity (and the correction of it by means of the proper
42 weight) and order of the calibration model (linear or quadratic). The LOD and LOQ were estimated
43 by means of the Hubaux-Vos' algorithm [23] applied in the linear dynamic range and corrected for
44 the heteroscedasticity weights [19].
45
46
47
48
49
50
51
52

53
54 To determine selectivity and specificity, the signal-to-noise ratio (S/N) was measured on the
55 selected ion chromatograms at the expected retention times for all the analytes of interest. The
56 presence of interfering peaks around the retention time of the analytes was identified by S/N values
57 higher than 3. Intra- and inter-day precision and accuracy were evaluated using two dedicated back-
58
59
60

1
2
3 calculation approaches, described elsewhere [19]. Optimal percent coefficient of variation (CV%)
4 and percent bias were expected to lie within $\pm 15\%$, while results within $\pm 25\%$ were still considered
5 satisfactory. Retention time repeatability was verified on 30 real hair samples together with blank
6 hair samples spiked at different concentration levels. Deviations below 1% from calibrators and
7 controls were considered acceptable. Carry-over effect was evaluated by injecting one blank
8 extracts after the highest point of each calibration curve: if the S/N ratio was lower than 3 for each
9 ion chromatogram the carry-over effect was considered negligible. The matrix effect was estimated
10 at the 2 pg/mg concentration levels by comparing the experimental results obtained from blank hair
11 samples and solutions of pure methanol, both spiked after the extraction step. The matrix effect for
12 each target analyte was expressed as the percentage ratio between the two measured concentrations.
13
14
15
16
17
18
19
20
21
22

23 **RESULTS AND DISCUSSION**

24
25
26 The optimized choice of LC conditions including column selection and mobile phase composition
27 and gradient resulted in satisfactory separation of all targeted analytes, comprising the closely
28 related fentanyl analog compounds present in the stock standard solution mixture. The whole
29 chromatographic run, comprehensive of the time required for column re-equilibration before the
30 following injection, was completed in 5 min. Retention times ranged between 2.76 min
31 (norfentanyl) and 4.28 min (4-fluorobutyrfentanyl). Figure 1 shows the TIC chromatogram recorded
32 from a blank hair spiked with all analytes at 100 pg/mg concentration.
33
34
35
36
37

38 *Validation*

39
40
41 Table 2 reports a summary of the observed results including the range of calibration, calibration
42 curve equations, LODs and LOQs values. For all the analytes, the calibration data-points proved to
43 have heteroscedastic distribution suggesting the homogeneous use of a $1/x^2$ weighting factor. The
44 calibration curves for all analytes proved linear within the calibration range, after lack-of-fit and
45 Mandel testing.
46
47
48
49

50
51 Retention time precision, selectivity and specificity proved satisfactory, and no interfering signals
52 were detected at the retention times of the target analytes. Inter-day and intra-day precision
53 (expressed as percent variation coefficient, CV%) and accuracy (expressed as bias%) were found to
54 be below 25% and 20%, respectively. The assay showed remarkable reproducibility for
55 concentrations ranging over three orders of magnitude, proving the robustness of the overall
56 workflow. Limits of detection (LOD) in matrix were found to be in the sub pg/mg range for most of
57
58
59
60

the target analytes used in this study (see Table 2). Lastly, the absence of any carry-over effect was observed. The validation results not reported in Table 2 are summarized in Table S2. The real hair matrix effect appeared to be significant for some of the analytes tested. However, the matrix effect is expected to be partly compensated by a well-matched internal standard, i.e. the isotopically-labeled analyte, whenever possible, or the one having similar retention time and structural features.

Targeted analysis of real samples

The large diffusion all over U.S. of fentanyl (and its analogs), either as substitute or cutting material of heroin, makes hair samples collected from habitual opiates users the ideal real matrices to test the robustness of the workflow developed in the present study. Unlike the selected reaction monitoring procedures commonly used in triple-quadrupole instruments to detect the targeted analytes, the SWATH™ Acquisition was chosen to produce complete high-resolution MS/MS spectra, enabling fully reliable identification based on several highly specific accurate mass fragment ions and library database matching. In practice, the SCIEX OS Software provides a centralized results grid that allows simultaneous quantification and library matching, displaying at the same time and within a single window the XIC, TOF-MS and MS/MS spectra of the candidate analyte with library search match. In addition, retention time, mass, isotope ratio error, and mass spectral library search score are automatically calculated and visualized. Figure 2 shows the successful detection of fentanyl, acetylfentanyl, furanylfentanyl and 4-fluorobutyrfentanyl from one of the tested head hair samples at concentrations of 420, 2, 120, and 36 pg/mg, respectively, together with the metabolites norfentanyl and 4-ANPP, at concentration of 18 and 230 pg/mg, respectively. The library fit scores (>99.0%) and the combined scores (>90%) provided excellent confidence for the definitive detection of these NSOs.

Overall, 70 samples out of 100 tested positive to at least one target analyte among the ones listed in Table 1. Fentanyl was the predominant synthetic opioid, being present in 68 hair samples with concentrations in the 1.2 – 1400 pg/mg range. Other prevalent analogs were furanylfentanyl (28 positive samples, range 1.2 – 6300 pg/mg) and acetyl fentanyl (14 positive samples, range 1.2 – 230 pg/mg). The metabolite norfentanyl was detected in 17 cases, with concentrations in the range 3.5 – 600 pg/mg, while the precursor/metabolite 4-ANPP was detected in 20 cases, with concentrations in the range 1.4 – 230 pg/mg. The complete panel of positive findings is reported in Table 3. Notably, carfentanil, methylfentanyl, and ocfentanil were not found in any of the analyzed samples.

Retrospective untargeted analysis of real samples

1
2
3 A major motivation for the use of SWATH™ Acquisition mode is the opportunity to detect
4 relevant analytes not included in the list of expected substances. While the availability of a pure
5 standard is necessary for accurate quantification, unexpected analytes can be identified with
6 confidence when high-resolution TOF-MS and MS/MS, and isotope distribution results are matched
7 with library data. However, this opportunity represents a serious challenge in the case of fentanyl
8 analogs and metabolites, because their extremely high biological activity is frequently consistent
9 with low administered dosages, further reducing the already minimal amount of drug partitioned in
10 the hair matrix. In the illegal market, the substances with the highest pharmacological potency and
11 lowest dosages are particularly attractive to dealers.

12
13
14
15
16
17
18
19 The retrospective untargeted analysis of the real samples considered in this study allowed the
20 identification of two fentanyl analogs which were not included in the panel of targeted analytes. In
21 one sample, the occurrence of β -hydroxyfentanyl was proposed as the best match from
22 ChemSpider, and afterwards confirmed by comparison with the analytical standard acquired on-
23 purpose. β -hydroxyfentanyl was originally sold as an illicit drug in the 1980s but its use has not
24 been reported since that time [24]. Very recently, a case of toxicity from intentional therapeutic use
25 of β -hydroxyfentanyl (possibly mistaken as fentanyl) was reported [25]. Furthermore, β -
26 hydroxyfentanyl had been detected in biological fluids as a metabolic product after fentanyl
27 administration [26,27], but it has never been reported in hair before.

28
29
30
31
32
33
34
35
36 The concurrent detection of metabolites of the taken substance in hair represents an essential step in
37 analytical toxicology to sustain the hypothesis of deliberate abuse and exclude the alternative
38 hypothesis of external contamination from the parent drug [4]. In this context, the identification of
39 β -hydroxyfentanyl can open new opportunities to assist the results interpretation in hair analysis,
40 even if further studies are needed to investigate its presence in a larger population of fentanyl-
41 positive samples and to evaluate the typical concentration ratio between parent drug and β -
42 hydroxyfentanyl. The proposed fragmentation scheme for β -hydroxyfentanyl is shown in Figure 3.
43 Major fragments include m/z 335 (corresponding to a water loss from the protonated molecular
44 ion), m/z 204 (corresponding to the hydroxyphenethyl-piperidine moiety), the subsequent water loss
45 (m/z 186) from m/z 204, and the tropylium cation at m/z 91 (formed from the phenethyl moiety). The
46 fragment m/z 132 is likely to correspond to the N-propenyl-aniline ion structure.

47
48
49
50
51
52
53
54
55
56 In a different sample, the software attributed a chromatographic peak to the presence of
57 methoxyacetylfentanyl. This compound is among the latest fentanyl analogs emerged onto the
58 recreational drug scene, potentially being sold to unsuspecting users as a contaminant or substitute
59 for heroin. As a new active substance, it has been linked to several intoxication cases, mostly lethal
60

[28,29]. To our knowledge, we present hereby the first tentative identification of this analyte in hair, based on literature data which should be confirmed as soon as a commercial reference standard will be available. The chemical formula of the methoxyacetylfentanyl protonated molecular ion was identified with an error of 0.6 ppm, while the proposed fragmentation pattern is shown in Figure 4. The fragments at m/z 188 and 105 are typical for fentanyl and its analogs. In particular, the fragment at m/z 188 is consistent with the phenethyl-piperidine moiety, while the fragment at m/z 105 corresponds to the phenethyl ion.

CONCLUSIONS

In the development of analytical methods, the prerequisite of multi-analytes protocols is that the list of the targeted substances includes all the molecules of interest expected to be possibly present in the screened samples. Unfortunately, the toxicological analyses dealing with the detection of NPS/NSO cannot be counted within such an ideal scenario. Quite often, new and unexpected compounds abruptly show up in the illegal market of drugs of abuse. While the existing targeted screening methods have proved remarkable sensitivity and specificity, their inability to detect new compounds which are not included in the panel of target analytes appears as a significant limitation. On the other hand, our approach based on SWATH acquisition proved its ability to identify the compounds at the very low levels typical of hair analysis, even when dealing with the potent (i.e. taken at low doses) NSOs. Furthermore, newly discovered NSOs can be added to the panel of target analytes to allow retrospective analysis of previously-acquired data to look for the presence of these new substances.

Broad-spectrum HRMS screening methods can become of particular interest owing to the challenges presented by NPS/NSO, and in particular for the continuous modification of drug scenarios in the black market. Furthermore, the retrospective investigation represents an added value for investigation of hair samples, especially when the small amount allows only one analysis, especially in forensic labs where there is a greater need to maximize the range of detectable compounds. Noteworthy, a screening result always needs a targeted confirmation analysis, especially in forensic cases. However, this is of lesser concern, when the target is already suspected. Indeed, the main challenge with new drugs is the initial identification of candidate drugs for further evaluation. In this scenario, our HRMS-based approach seems very promising and innovative. The only limitation is that the described method still relies on a mass spectral library and an add-on software generating candidate empirical formula. However, with the rapid growth of NPS/NSO, it is

likely that HRMS instruments will become increasingly prevalent as forensic screening tools. We envision that our approach can assist national programs of drug surveillance. Indeed, the development of comprehensive screening methods will provide law enforcement agencies and health professionals alike a clearer picture of the long-term use of these drugs and their evolution in the consumer market. Furthermore, the retrospective data analysis feature will become a powerful tool when a new drug is reported for the first time in a certain territory, allowing the monitoring of past consumption trends in specific populations and at different times.

Acknowledgements

M. Kolia carried out part of this work within the framework of the Erasmus+ Program.

References

1. Ciccarone D. The triple wave epidemic : Supply and demand drivers of the US opioid overdose crisis. *Int J Drug Policy*. 2019;71:183–8.
2. Zoorob M. Fentanyl shock: The changing geography of overdose in the United States. *Int J Drug Policy*. 2019;70:40–6.
3. Jones CM, Einstein EB, Compton WM. Changes in synthetic opioid involvement in drug overdose deaths in the United States, 2010-2016. *JAMA - J Am Med Assoc*. 2018;319(17):1819–21.
4. Kintz P, Salomone A, Vincenti M. *Hair Analysis in Clinical and Forensic Toxicology* 2015. Available from: <http://www.elsevier.com/books/hair-analysis-in-clinical-and-forensic-toxicology/kintz/978-0-12-801700-5>
5. Salomone A, Bigiarini R, Di Corcia D, Vincenti M. Interpretation of hair analysis for fentanyl and analogues. *Toxicol Anal Clin*. 2019;31(2):S15–6.
6. Salomone A, Palamar JJ, Bigiarini R, Gerace E, Di Corcia D, Vincenti M. Detection of Fentanyl Analogs and Synthetic Opioids in Real Hair Samples. *J Anal Toxicol*. 2019;43(4).
7. Salomone A, Bigiarini R, Palamar JJ, McKnight C, Vinsick L, Amante E, et al. Toward the Interpretation of Positive Testing for Fentanyl and Its Analogs in Real Hair Samples: Preliminary Considerations. *J Anal Toxicol*. 2020;44(4):362–9.
8. Fabresse N, Larabi IA, Stratton T, Mistrik R, Pfau G, Lorin de la Grandmaison G, et al. Development of a sensitive untargeted liquid chromatography–high resolution mass

- 1
2
3 spectrometry screening devoted to hair analysis through a shared MS2 spectra database: A
4 step toward early detection of new psychoactive substances. *Drug Test Anal.*
5 2019;11(5):697–708.
6
7
8
- 9 9. Larabi IA, Martin M, Fabresse N, Etting I, Edel Y, Pfau G, et al. Hair testing for 3-
10 fluorofentanyl, furanylfentanyl, methoxyacetylfentanyl, carfentanil, acetylfentanyl and
11 fentanyl by LC–MS/MS after unintentional overdose. *Forensic Toxicol.* 2020;38(1):277–86.
12
13
14
- 15 10. Palamar JJ, Salomone A, Bigiarini R, Vincenti M, Acosta P, Tofighi B. Testing hair for
16 fentanyl exposure: a method to inform harm reduction behavior among individuals who use
17 heroin. *Am J Drug Alcohol Abuse.* 2019;45(1):90–6.
18
19
20
- 21 11. Busardò FP, Carlier J, Giorgetti R, Tagliabracci A, Pacifici R, Gottardi M, et al. Ultra-High-
22 Performance Liquid Chromatography-Tandem Mass Spectrometry Assay for Quantifying
23 Fentanyl and 22 Analogs and Metabolites in Whole Blood, Urine, and Hair. *Front Chem.*
24 2019;7:184, 10.3389/fchem.2019.00184
25
26
27
- 28 12. Rosado T, Barroso M, Vieira DN, Gallardo E. Determination of Selected Opiates in Hair
29 Samples Using Microextraction by Packed Sorbent: A New Approach for Sample Clean-up.
30 *J Anal Toxicol.* 2019;43(6):465–76.
31
32
33
- 34 13. Larabi IA, Martin M, Etting I, Pfau G, Edel Y, Alvarez JC. Development and validation of
35 liquid chromatography-tandem mass spectrometry targeted screening of 16 fentanyl analogs
36 and U-47700 in hair : Application to 137 authentic samples. *Drug Test Anal.* 2020;
37 <https://doi.org/10.1002/dta.2868>
38
39
40
41
- 42 14. Freni F, Moretti M, Radaelli D, Carelli C, Marco A, Osculati M, et al. Determination of
43 fentanyl and 19 derivatives in hair : Application to an Italian population. *J Pharm Biomed*
44 *Anal.* 2020;189:113476.
45
46
47
- 48 15. Salomone A, Palamar JJ, Vincenti M. Should NPS be included in workplace drug testing ?
49 2020;191–4.
50
51
52
- 53 16. Noble C, Weihe Dalsgaard P, Stybe Johansen S, Linnet K. Application of a screening method
54 for fentanyl and its analogues using UHPLC-QTOF-MS with data-independent acquisition
55 (DIA) in MSE mode and retrospective analysis of authentic forensic blood samples. *Drug*
56 *Test Anal.* 2018;10(4):651–62.
57
58
59
- 60 17. Krotulski AJ, Mohr ALA, Logan BK. Emerging Synthetic Cannabinoids : Development and

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Validation of a Novel Liquid Chromatography Quadrupole Time-of-Flight Mass Spectrometry Assay for Real-Time Detection. *J Anal Toxicol.* 2020;44(3):207-217

18. Little JL, Williams AJ, Pshenichnov A, Tkachenko V. Identification of “ Known Unknowns ” Utilizing Accurate Mass Data and ChemSpider. *J. Am. Soc. Mass Spectrom.* 2012;23:179–185
19. Alladio E, Amante E, Bozzolino C, Seganti F, Salomone A, Vincenti M, et al. Effective validation of chromatographic analytical methods: The illustrative case of androgenic steroids. *Talanta* 2020;215:120867.
20. Alladio E, Amante E, Bozzolino C, Seganti F, Salomone A, Vincenti M, et al. MethodsX Experimental and statistical protocol for the effective validation of chromatographic analytical methods. *MethodsX.* 2020;7:100919.
21. Desharnais B, Camirand-Lemyre F, Mireault P, Skinner CD. Procedure for the selection and validation of a calibration model II-theoretical basis. *J Anal Toxicol.* 2017;41(4):269–76.
22. Desharnais B, Camirand-Lemyre F, Mireault P, Skinner CD. Procedure for the Selection and Validation of a Calibration Model I—Description and Application. *J Anal Toxicol.* 2017;41(4):261–8.
23. Hubaux A, Vos G. Decision and detection limits for calibration curves. *Anal Chem.* 1970;42(8):849–55.
24. Henderson G. Designer drugs: past history and future prospects. *J Forensic Sci.* 1988;33(2):569–75.
25. Hendrickson RG, Akpunonu P, Hughes AR, Gerona R. Highly potent fentanyl analogs: apnea from exposure to small quantities of β -hydroxyfentanyl and furanylfentanyl. *Clin Toxicol.* 2019;57(9):813–5.
26. Labroo RB, Paine MF, Thummel KE, Kharasch ED. Fentanyl metabolism by human hepatic and intestinal cytochrome P450 3A4: Implications for interindividual variability in disposition, efficacy, and drug interactions. *Drug Metab Dispos.* 1997;25(9):1072–80.
27. Wallgren J, Vikingsson S, Rautio T, Nasr E, Åstrand A, Watanabe S, et al. Structure Elucidation of Urinary Metabolites of Fentanyl and Five Fentanyl Analogs using LC-QTOF-MS , Hepatocyte Incubations and Synthesized Reference Standards. 2020;

1
2
3 doi.org/10.1093/jat/bkaa021.
4

- 5
6 28. Mardal M, Johansen SS, Davidsen AB, Telving R, Jornil JR, Dalsgaard PW, et al.
7 Postmortem analysis of three methoxyacetylfentanyl-related deaths in Denmark and in vitro
8 metabolite profiling in pooled human hepatocytes. *Forensic Sci Int.* 2018;290:310–7.
9
10
11 29. Fogarty MF, Papsun DM, Logan BK. Analysis of Fentanyl and 18 Novel Fentanyl Analogs
12 and Metabolites by LC-MS-MS, and report of Fatalities Associated with
13 Methoxyacetylfentanyl and Cyclopropylfentanyl. *J Anal Toxicol.* 2018;42(9):592–604.
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 1 TIC chromatogram recorded from a blank hair spiked with all analytes at 100 pg/mg concentration. The order of elution is as follows: 1) norfentanyl, 2) acetylfentanyl, 3) ocfentanyl, 4) acrylfentanyl, 5) 4-ANPP, 6) fentanyl, 7) furanylfentanil, 8) α -Methylfentanyl, 9) cyclopropylfentanyl, 10) carfentanil, 11) butyrfentanyl, 12) 4-fluorobutyrfentanyl

Figure 2 Extracted ion chromatograms (mass tolerance \pm 5 ppm) from a real sample positive to fentanyl (420 pg/mg), norfentanyl (18 pg/mg), 4-ANPP (230 pg/mg), acetylfentanyl (2.2 pg/mg), furanylfentanyl (120 pg/mg) and 4-fluorobutyrfentanyl (36 pg/mg).

Figure 3 SWATH TOF-MS/MS spectrum and predominant fragmentation pattern of β -hydroxyfentanyl as observed in a real hair sample.

Figure 4 SWATH TOF-MS/MS spectrum and predominant fragmentation pattern of methoxyacetylfentanyl as observed in a real hair sample.

For Peer Review




Figure 1

242x132mm (300 x 300 DPI)




Figure 2

131x134mm (300 x 300 DPI)




Figure 3

348x147mm (300 x 300 DPI)




Figure 4

343x150mm (300 x 300 DPI)

| | Name | Elemental composition | Precursor ion | Precursor (Q1) calculated mass (Da) | Fragment (Q3) calculated mass (Da) |
|-----|------------------------------------|--|--------------------|--|---------------------------------------|
| 1 | Norfentanyl | C ₁₄ H ₂₀ N ₂ O | [M+H] ⁺ | 233.1648 | 84.0808 |
| 2 | Acetylfentanyl | C ₂₁ H ₂₆ N ₂ O | [M+H] ⁺ | 323.2118 | 188.1434 |
| 3 | Ocfentanil | C ₂₂ H ₂₇ FN ₂ O ₂ | [M+H] ⁺ | 371.2129 | 188.1434 |
| 4 | Acrylfentanyl | C ₂₂ H ₂₆ N ₂ O | [M+H] ⁺ | 335.2118 | 188.1434 |
| 5 | 4-ANPP | C ₁₉ H ₂₄ N ₂ | [M+H] ⁺ | 281.2012 | 188.1434 |
| 6 | Fentanyl | C ₂₂ H ₂₈ N ₂ O | [M+H] ⁺ | 337.2274 | 188.1434 |
| 7 | Furanylfentanil | C ₂₄ H ₂₆ N ₂ O ₂ | [M+H] ⁺ | 375.2067 | 188.1434 |
| 8 | α-Methylfentanyl | C ₂₃ H ₃₀ N ₂ O | [M+H] ⁺ | 351.2431 | 202.159 |
| 9 | Cyclopropylfentanyl | C ₂₃ H ₂₈ N ₂ O | [M+H] ⁺ | 349.2274 | 188.1434 |
| 10 | Carfentanil | C ₂₄ H ₃₀ N ₂ O ₃ | [M+H] ⁺ | 395.2329 | 335.2118 |
| 11 | Butyrfentanyl | C ₂₃ H ₃₀ N ₂ O | [M+H] ⁺ | 351.2431 | 188.1434 |
| 12 | 4-fluorobutyrfentanyl | C ₂₃ H ₂₉ FN ₂ O | [M+H] ⁺ | 369.2337 | 188.1434 |
| IS1 | Norfentanyl- <i>d</i> ₅ | C ₁₄ H ₁₅ ² H ₅ N ₂ O | [M+H] ⁺ | 238.1962 | - |
| IS2 | Fentanyl- <i>d</i> ₅ | C ₂₂ H ₂₃ ² H ₅ N ₂ O | [M+H] ⁺ | 342.2588 | 188.1434 |

Table 1 Full list of the MS/MS transitions for analytes and internal standards

| Compound | Internal Standard | Calibration range (pg/mg) | Weight | Calibration curve | LOD (pg/mg) | LOQ (pg/mg) |
|--------------------------|------------------------------------|---------------------------|--------------------------|-----------------------|-------------|-------------|
| 1 Norfentanyl | Norfentanyl- <i>d</i> ₅ | 2.0-100 | 1/ <i>x</i> ² | 3.31 <i>x</i> + 0.04 | 1.2 | 2.4 |
| 2 Acetylfentanyl | Fentanyl- <i>d</i> ₅ | 2.0-100 | 1/ <i>x</i> ² | 4.46 <i>x</i> + 0.03 | 0.6 | 1.2 |
| 3 Ocfentanil | Fentanyl- <i>d</i> ₅ | 2.0-100 | 1/ <i>x</i> ² | 3.57 <i>x</i> + 0.01 | 0.4 | 0.8 |
| 4 Acrylfentanyl | Fentanyl- <i>d</i> ₅ | 2.0-100 | 1/ <i>x</i> ² | 3.48 <i>x</i> + 0.01 | 0.6 | 1.2 |
| 5 4-ANPP | Fentanyl- <i>d</i> ₅ | 2.0-100 | 1/ <i>x</i> ² | 3.78 <i>x</i> + 0.01 | 0.7 | 1.4 |
| 6 Fentanyl | Fentanyl- <i>d</i> ₅ | 2.0-100 | 1/ <i>x</i> ² | 4.58 <i>x</i> + 0.02 | 0.6 | 1.2 |
| 7 Furanylfentanyl | Fentanyl- <i>d</i> ₅ | 2.0-100 | 1/ <i>x</i> ² | 5.79 <i>x</i> + 0.02 | 0.6 | 1.2 |
| 8 α-Methylfentanyl | Fentanyl- <i>d</i> ₅ | 2.0-100 | 1/ <i>x</i> ² | 2.32 <i>x</i> - 0.002 | 0.5 | 1.0 |
| 9 Cyclopropylfentanyl | Fentanyl- <i>d</i> ₅ | 2.0-100 | 1/ <i>x</i> ² | 3.57 <i>x</i> + 0.02 | 0.7 | 1.4 |
| 10 Carfentanil | Fentanyl- <i>d</i> ₅ | 2.0-100 | 1/ <i>x</i> ² | 3.26 <i>x</i> + 0.002 | 0.8 | 1.6 |
| 11 Butyrfentanyl | Fentanyl- <i>d</i> ₅ | 2.0-100 | 1/ <i>x</i> ² | 4.10 <i>x</i> + 0.02 | 0.6 | 1.2 |
| 12 4-fluorobutyrfentanyl | Fentanyl- <i>d</i> ₅ | 2.0-100 | 1/ <i>x</i> ² | 3.49 <i>x</i> + 0.02 | 0.2 | 0.4 |

Table 2 Validated parameters for the targeted screening

Table 3 Summary of results obtained from 100 real hair samples

| Target analyte | Number of positive samples | Range of concentrations (pg/mg) | Mean pg/mg | Median pg/mg |
|-----------------------|----------------------------|---------------------------------|------------|--------------|
| Fentanyl | 68 | LOQ–1400 | 93 | 17 |
| Norfentanyl | 17 | 3.5–600 | 69 | 8.4 |
| Acetylfentanyl | 14 | LOQ–230 | 29 | 2.5 |
| Furanylfentanyl | 28 | LOQ–6300 | 310 | 8.4 |
| Acrylfentanyl | 2 | LOQ | - | - |
| 4-fluorobutyrfentanyl | 6 | 5.2 – 180 | 69 | 24 |
| Cyclopropylfentanyl | 1 | 4.7 | - | |
| Butyrfentanyl | 1 | 54 | | |
| 4-ANPP | 20 | 1.4–230 | 22 | 4.1 |

For Peer Review

| Compound | Elemental composition | Protonated Exact mass (Da) |
|-------------------------------|---|----------------------------|
| Norfentanyl | C ₁₄ H ₂₀ N ₂ O | 233.1648 |
| Butyrylnorfentanyl | C ₁₅ H ₂₂ N ₂ O | 247.1805 |
| N-methylnorfentanyl | C ₁₅ H ₂₂ N ₂ O | 247.1805 |
| 4-anilino-benzylpiperidine | C ₁₈ H ₂₂ N ₂ | 267.1856 |
| Furanylnorfentanyl | C ₁₆ H ₁₈ N ₂ O ₂ | 271.1441 |
| 4-ANPP | C ₁₉ H ₂₄ N ₂ | 281.2012 |
| Norcarfentanil | C ₁₆ H ₂₂ N ₂ O ₃ | 291.1703 |
| Despropionyl p-fluorofentanyl | C ₁₉ H ₂₃ FN ₂ | 299.1918 |
| Acetylfentanyl | C ₂₁ H ₂₆ N ₂ O | 323.2118 |
| Benzylfentanyl | C ₂₁ H ₂₆ N ₂ O | 323.2118 |
| Methylthiofentanyl | C ₂₁ H ₂₈ N ₂ O | 325.2274 |
| U-47700 | C ₁₆ H ₂₂ Cl ₂ N ₂ O | 329.1182 |
| AH-7921 | C ₁₆ H ₂₂ Cl ₂ N ₂ O | 329.1182 |
| Thienylfentanyl | C ₁₉ H ₂₄ N ₂ OS | 329.1682 |
| Acrilfentanyl | C ₂₂ H ₂₆ N ₂ O | 335.2118 |
| Fentanyl | C ₂₂ H ₂₈ N ₂ O | 337.2274 |
| Methylacetylfentanyl | C ₂₂ H ₂₈ N ₂ O | 337.2274 |
| Thiofentanyl | C ₂₀ H ₂₆ N ₂ OS | 343.1839 |
| Cyclopropylfentanyl | C ₂₃ H ₂₈ N ₂ O | 349.2274 |
| Crotonylfentanyl | C ₂₃ H ₂₈ N ₂ O | 349.2274 |
| MT-45 | C ₂₄ H ₃₂ N ₂ | 349.2638 |
| Methylfentanyl | C ₂₃ H ₃₀ N ₂ O | 351.2431 |
| Butyrfentanyl | C ₂₃ H ₃₀ N ₂ O | 351.2431 |
| Isobutyrylfentanyl | C ₂₃ H ₃₀ N ₂ O | 351.2431 |
| Hydroxyfentanyl | C ₂₂ H ₂₈ N ₂ O ₂ | 353.2224 |
| Methoxyacetylfentanyl | C ₂₂ H ₂₈ N ₂ O ₂ | 353.2224 |
| Fluorofentanyl | C ₂₂ H ₂₇ FN ₂ O | 355.2180 |
| U-49900 | C ₁₈ H ₂₆ Cl ₂ N ₂ O | 357.1495 |
| Hydroxythiofenatnyl | C ₂₀ H ₂₆ N ₂ O ₂ S | 359.1788 |
| Valeryl fentanyl | C ₂₄ H ₃₂ N ₂ O | 365.2587 |
| Methylbutyrylfentanyl | C ₂₄ H ₃₂ N ₂ O | 365.2587 |
| para-methoxyfentanyl | C ₂₃ H ₃₀ N ₂ O ₂ | 367.2380 |
| Methoxyfentanyl | C ₂₃ H ₃₀ N ₂ O ₂ | 367.2380 |
| U-50488 | C ₁₉ H ₂₆ Cl ₂ N ₂ O | 369.1495 |
| 4-fluorobutyrfentanyl | C ₂₃ H ₂₉ FN ₂ O | 369.2337 |
| Fluorobutyrylfentanyl | C ₂₃ H ₂₉ FN ₂ O | 369.2337 |
| Chlorofentanyl | C ₂₂ H ₂₇ ClN ₂ O | 371.1885 |
| Ocfentanil | C ₂₂ H ₂₇ FN ₂ O ₂ | 371.2129 |
| Furanylfentanil | C ₂₄ H ₂₆ N ₂ O ₂ | 375.2067 |
| W-15 | C ₁₉ H ₂₁ ClN ₂ O ₂ S | 377.1085 |
| Cyclopentylfentanyl | C ₂₅ H ₃₂ N ₂ O | 377.2587 |
| Benzylcarfentanil | C ₂₃ H ₂₈ N ₂ O ₃ | 381.2173 |
| Methoxybutyrylfentanyl | C ₂₄ H ₃₂ N ₂ O ₂ | 381.2537 |
| Chloroisobutyrylfentanyl | C ₂₃ H ₂₉ ClN ₂ O | 385.2041 |
| Phenylfentanyl | C ₂₆ H ₂₈ N ₂ O | 385.2274 |
| W-19 | C ₁₉ H ₂₂ ClN ₃ O ₂ S | 392.1194 |
| Carfentanil | C ₂₄ H ₃₀ N ₂ O ₃ | 395.2329 |
| W-18 | C ₁₉ H ₂₀ ClN ₃ O ₄ S | 422.0936 |
| Benzodioxole fentanyl | C ₂₇ H ₂₈ N ₂ O ₃ | 429.2173 |

Table S1 Non-targeted screening of Novel Synthetic Opioids

For Peer Review

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table S2. Intra-day and inter-day accuracy and precision results calculated at 2, 10 and 100 pg/mg, plus recovery and matrix effect for all analytes.

| Analyte | Accuracy (bias%) | | | | | | Precision (CV%) | | | | | | Matrix effect (±%) |
|-----------------------|---------------------------|-----|-----|---------------------------|-----|-----|---------------------------|----|-----|---------------------------|----|-----|---------------------------|
| | Intra-day | | | Inter-day | | | Intra-day | | | Inter-day | | | |
| | Calibration level (pg/mg) | | | Calibration level (pg/mg) | | | Calibration level (pg/mg) | | | Calibration level (pg/mg) | | | |
| | 2 | 10 | 100 | 2 | 10 | 100 | 2 | 10 | 100 | 2 | 10 | 100 | Calibration level 2 pg/mg |
| Norfentanyl | 0 | 9 | -16 | 19 | 15 | 13 | 22 | 23 | 12 | 18 | 15 | 12 | +17.50 |
| Acetylfentanyl | 6 | -14 | 8 | 2 | -8 | -3 | 25 | 7 | 3 | 24 | 14 | 6 | -18.40 |
| Ocfentanil | 2 | -5 | 13 | 1 | -7 | -3 | 17 | 8 | 4 | 11 | 16 | 10 | -58.10 |
| Acrylfentanyl | 4 | -10 | 7 | 5 | -8 | 0 | 24 | 9 | 5 | 25 | 19 | 13 | -59.63 |
| 4-ANPP | 3 | -3 | 12 | 4 | -11 | 2 | 11 | 11 | 3 | 15 | 17 | 12 | -18.16 |
| Fentanyl | 6 | -11 | 8 | 4 | -10 | -2 | 24 | 7 | 4 | 19 | 13 | 6 | -46.10 |
| Furanylfentanyl | 5 | -11 | 8 | 2 | -6 | -3 | 18 | 8 | 3 | 22 | 12 | 7 | -36.00 |
| α-Methylfentanyl | 5 | -9 | 10 | 4 | -6 | -1 | 19 | 7 | 3 | 21 | 22 | 10 | -59.60 |
| Cyclopropylfentanyl | 8 | -5 | 5 | 5 | -9 | 0 | 18 | 7 | 3 | 17 | 17 | 11 | -46.24 |
| Carfentanil | 7 | -9 | 2 | -5 | -10 | -1 | 24 | 8 | 4 | 25 | 12 | 9 | -42.16 |
| Butyrfentanyl | 4 | -3 | 5 | 4 | -4 | -3 | 18 | 7 | 4 | 24 | 15 | 10 | -52.10 |
| 4-fluorobutyrfentanyl | 17 | -2 | 5 | 4 | -4 | -3 | 12 | 9 | 3 | 17 | 16 | 14 | -48.94 |